Cesare Colosimo1, Mieczyslaw Pasowicz2, Phillipe Demaerel3, Paolo Tortori-Donati4, Pei-yi Gao5, Matthew J. Kuhn6
1Neuroradiology, 1Catholic University of the Sacred Heart, Rome, Italy; 2Radiology, Krakow Hospital John Paul II, Krakow, Poland; 3Radiology, University Hospital K.U. Leuven, Leuven, Belgium; 4Radiology, Institute G. Gaslini, Genoa, Italy; 5Radiology, Beijing Tian Tan Hospital, Beijing, China; 6Radiology, Southern Illinoias University School of Medicine, Springfield, IL, USA
The pharmacokinetics, safety, and efficacy of gadobenate dimeglumine (Gd-BOPTA)for enhanced MRI of the CNS in children were evaluated. Pharmacokinetics of Gd-BOTPA best fit a 2-compartment model, with >80% recovery in urine at 24 hours. The overall adverse event (AE) rate was 11.6% (18/151). In a comparison study, the AE rate after Gd-BOPTA (13%) and gadopentetate dimeglumine (Gd-DTPA) (14%) was similar (p=0.75). Lesion enhancement with Gd-BOPTA was good-to-excellent, resulting in improved lesion border delineation, visualization of internal morphology, and definition of disease extent. Compared to an equal dose of Gd-DTPA, postdose changes in lesion visualization were significantly (p≤0.011) greater for Gd-BOPTA than Gd-DTPA.